906 results about "Granulocytic cells" patented technology

This disclosure relates to a method of treating a neurological disorder, comprising administering a bupropion, or a combination of a bupropion and a dextromethorphan, to a human being in need thereof, monitoring the human being for Brugada pattern / syndrome, drug reaction with eosinophilia and systemic symptoms, or acute generalized exanthematous pustulosis, and reducing or discontinuing use of the bupropion, or the combination of the bupropion and the dextromethorphan, if the human being develops Brugada pattern / syndrome, subcutaneous tissue disorder, drug reaction with eosinophilia and systemic symptoms (DRESS), or acute generalized exanthematous pustulosis.

A G1T38 human oral dosage regime that provides a (mean AUC(0-24),ss (h*ng / mL)) / (dose (mg)) ratio of less than 5 and / or a (mean AUC(0-24),ss (h*ng / mL)) / (Absolute Neutrophil Count (cells / mm3)) ratio on day 22 of dosing of not greater than 1.25.

The invention belongs to the technical field of biological medicines, and particularly relates to application of a targeted liposome as an active component in preparation of a medicine for treating ischemic brain injury. The targeted lipidosome for treating cerebral arterial thrombosis is prepared by fusing the lipidosome and the platelet-neutrophil aggregate membrane, realizes efficient and specific targeting of an ischemic brain region, effectively reduces brain tissue infarction and damage of a new region, relieves brain inflammation through multi-channel regulation and control, and improves the cerebral arterial thrombosis treatment effect. The compound can be used as an active ingredient for preparing a medicine for treating ischemic brain injury. And after the target liposome is further coated with a rutin drug, the synergistic treatment effect is realized. The liposome medicine can be used as an active component and has a good application prospect in treatment of ischemic brain injury diseases.

The invention relates to the field of biological imaging, and particularly discloses an in-vitro cell microenvironment dynamic monitoring method for two-photon frequency domain fluorescence lifetime imaging, which comprises the following steps: S1, by using a two-photon frequency domain fluorescence lifetime imaging TP-FD-FLIM technology, losslessly representing microenvironment change through fluorescence lifetime parameters, and monitoring oxidative stress reaction and neutrophil migration behavior in real time, analyzing the effect of the associated compound in combination with an in-vitro cell model; and S2, based on the physical basis of FD-FLIM, establishing a frequency domain fluorescence lifetime signal processing and analysis system under periodic excitation, analyzing the dynamic correlation characteristics of the phase delay phi and the modulation depth M of a fluorescence signal relative to exciting light, and carrying out quantitative backstepping on molecular lifetime parameters. According to the in-vitro cell microenvironment dynamic monitoring method for two-photon frequency domain fluorescence lifetime imaging provided by the invention, neuroinflammatory response can be observed in a lossless and real-time manner on the subcellular scale.

The invention provides a strain of lactobacillus plantarum YS-AG23 with high antioxidant activity, and a rhizoma polygonati and radix angelicae sinensis fermented product obtained by fermenting rhizoma polygonati and radix angelicae sinensis with the strain of lactobacillus plantarum YS-AG23. In a D-galactose induced premature ovarian failure mouse model, the fermentation product can regulate up the levels of antioxidant and stress protection genes SOD2 and HO-1 and an anti-aging gene SIRT1 by regulating down the expression of a key gene AGER of an inflammation and oxidative stress pathway, so that the oxidative stress and inflammatory response of model mouse ovarian tissues are remarkably reduced; meanwhile, the serum hormone level can be specifically adjusted, the serum estradiol (E2) level can be increased, the follicle stimulating hormone (FSH) and luteinizing hormone (LH) levels can be reduced to be close to the normal range, the expression of anti-mullerian hormone (AMH) and hormone regulatory gene LHR of ovarian reserve markers can be up-regulated, the proliferative activity and estrogen secretion function of follicular granulosa cells can be improved, and the effect of preventing ovarian reserve is achieved. The wet weight of atrophic uterus and ovary of the model mouse is remarkably increased, uterine and ovary atrophy is effectively reversed, and the ovarian reserve function of the D-galactose induced premature ovarian failure model mouse is recovered. Besides, in an H2O2-induced human dermal fibroblast aging model, the yeast can improve the activity of aging cells in a concentration-dependent manner and reduce the level of reactive oxygen species (ROS) in the cells; in addition, by up-regulating the expression of a collagen synthesis key gene COL1A1 and down-regulating the expression of a cell senescence marker gene p16, skin cell senescence caused by oxidative stress can be effectively improved. In conclusion, the polygonatum sibiricum and angelica sinensis leavening can synchronously improve premature ovarian failure and skin cell senescence caused by oxidative stress by accurately regulating and controlling oxidative stress, inflammatory response and tissue function related genes, and has wide application potential.

The present invention is directed to orally administered compositions of topically acting corticosteroids for the treatment of inflammation of the gastrointestinal tracts such as eosinophilic esophagitis. The present invention also provides a method for treating conditions associated with inflammation of the gastrointestinal tract in an individual. The method comprises administering to an individual in need thereof a pharmaceutical composition of the present invention as orally disintegrating tablets comprising a topically active corticosteroid adsorbed onto a pharmaceutically acceptable carrier such as silicified microcrystalline cellulose.

The invention discloses an application of the number of neutrophils in predicting the curative effect of oncolytic viruses in treating tumors. In the application, the neutrophile granulocyte number level in the blood of a tumor patient is closely associated with the tumor treatment effect, and the applicable tumor syndromes are common, including melanoma, colorectal cancer, esophageal cancer, head and neck tumors, gastric cancer, biliary tract system tumors, sarcoma and other tumors. In the application, the critical value of the number of neutrophils for predicting the tumor treatment effect is 2 * 10 < 9 >-5.5 * 10 < 9 > / L, and the most preferable critical value is 4.0 * 10 < 9 > / L; the curative effect of OH2 single-drug treatment on tumor patients with the neutrophil number level below a critical value is better than that of tumor patients with the neutrophil number level above the critical value.

The invention provides a biomarker for diagnosing systemic lupus erythematosus and application of the biomarker. According to the application disclosed by the invention, the expression of Ferritin in neutrophil of a systemic lupus erythematosus patient is found to be obviously reduced and is improved after treatment, the neutrophil has disease specificity and cell specificity, and the Ferritin in the neutrophil has important significance on clinical diagnosis or auxiliary diagnosis of systemic lupus erythematosus and disease condition evaluation.

The present invention relates to a binding agent capable of specifically binding and competitively inhibiting neutrophil elastase, the binding agent comprising an immunoglobulin single variable domain (ISVD), as well as related products, methods and uses, for example, methods and uses, particularly for the prevention, treatment or diagnosis of inflammatory diseases.

A blood cell analyzer (100) and a blood cell analysis method (300). The blood cell analysis method (300) comprises: sucking a blood sample to be tested; preparing a first determination sample and obtaining first optical information; preparing a second determination sample and obtaining second optical information; generating a first leukocyte classification scatter diagram and a second leukocyte classification scatter diagram; determining a first counting result of neutrophils of the to-be-detected blood sample based on the first leukocyte classification scatter diagram and the second leukocyte classification scatter diagram; determining an actual distribution area of neutrophils from the first leukocyte classification scatter diagram; based on a reference distribution region of neutrophils of a reference leukocyte classification scatter diagram of the normal blood sample, determining a leaf-division nucleophore distribution region from the actual distribution region; determining a second counting result of the cells falling into the leaf-separating nucleogranulocyte distribution area; and based on the first counting result and the second counting result, determining a counting result of the rod-shaped nuclear granulocytes in the to-be-detected blood sample.

The invention provides a culture system for simulating neutrophile granulocyte extracellular trap net intervention oligodendrocyte in vitro, and belongs to the technical field of cell and function detection. The invention establishes a stable and repeatable research system by screening and determining the optimal condition for in-vitro co-culture of the neutrophil extracellular trap net and the oligodendroglia. Based on the condition, the experiment can observe the obvious change of the oligodendroglia after the intervention, and the result shows that the condition can accurately simulate the endoplasmic reticulum stress regulation effect of the neutrophile granulocyte extracellular trap net on the oligodendroglia, thereby providing a necessary experimental basis for the subsequent mechanism research.

The invention discloses a preparation method and application of a novel hybrid extracellular vesicle. According to the invention, vesicles derived from endothelial cells and neutrophil cells are combined with deferoxamine, and a biological mixed nano vesicle platform (DFO (HEVS)) is developed to solve the problem of diabetes wound healing. According to the dual-targeting system, DFO is accurately delivered to a wound part by utilizing CXCR4 mediated endothelial cell homing and beta2 integrin dependent inflammation tropism, DFO (at) HEVs activates and recovers vascular regeneration through HIF-1alpha / VEGF, ferroptosis is inhibited through Nrf2 / GPX4 signal transduction, macrophages are reprogrammed into a repair promoting M2 phenotype, and oxidative stress-inflammation-ferroptosis circulation is effectively broken.

The present disclosure provides methods of treating inflammation of the upper gastrointestinal tract, especially the esophagus, by administering an oral corticosteroid. In some cases, the methods include treating eosinophilic esophagitis (EoE) by administering an oral corticosteroid in an induction phase and a maintenance phase to improve peak eosinophilic counts and symptoms. In embodiments, the methods include treating EoE by administering the oral corticosteroid at nighttime and / or while the patient is lying down.

The invention discloses a monoclonal antibody which only specifically recognizes neutrophil apolipoprotein homodimer HNL / HNL and does not recognize monomer form HNL. The amino acid sequence of a heavy chain variable region of the antibody is as shown in SEQ ID NO.1, and the amino acid sequence of a light chain variable region of the antibody is as shown in SEQ ID NO.5. The monoclonal antibody realizes accurate, simple and rapid quantification of homodimer form HNL / HNL, promotes wide clinical application of the detection index, accurately distinguishes bacterial infection and virus infection, and reduces unreasonable use of antibiotics.

The present subject matter relates to recombinant lentiviral transfer plasmids for producing lentiviral vectors with increased vector titer and performance. These transfer plasmids are constructed so that a central polypurine tract (cPPT) is centered between the lentiviral LTRs and include a 6x stop codon sequence block downstream of the 3' LTR. When the transfer plasmids comprise a globin expression cassette, the lentiviral vectors produced therefrom are useful for treating hemoglobinopathies by gene therapy. Transduced cells, pharmaceutical compositions and methods of treating or ameliorating hemoglobinopathies with these lentiviral vectors are also provided. Additional transfer plasmids, cells, and compositions are provided that are useful for delivering any gene of interest to a cell, as well as plasmids for production of lentiviral vectors for treating other erythroid-specific diseases or disorders such as anemia and cancer.

The invention belongs to the field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine composition for treating sepsis-related acute lung injury and application thereof. The traditional Chinese medicine composition comprises the following active pharmaceutical ingredients in parts by mass: 5-15 parts of cassia twig, 5-15 parts of rheum officinale, 10-20 parts of peach kernel, 25-35 parts of gypsum and 10-20 parts of kudzu vine root. Animal experiments show that the traditional Chinese medicine composition can effectively improve lung tissue pathological manifestations of mice with sepsis-related acute lung injury by inhibiting polarization of M1 type macrophages, promoting polarization of M2 type macrophages, improving the infiltration level of neutrophils and inhibiting release of inflammatory factors. Therefore, the traditional Chinese medicine composition disclosed by the invention has a good treatment effect on acute lung injury related to sepsis.

The invention relates to the technical field of medical treatment, and particularly discloses a compound prognosis model for cancer prognosis evaluation, a prognosis evaluation method and a calculator. The compound prognosis model is constructed based on inflammation burden related prognosis indexes ALNCR and TNM by stage combination; the creation method comprises the following steps: step 1, collecting albumin concentration, lymphocyte count, neutrophil count and C-reactive protein concentration data of a cancer patient; 2, calculating an ALNCR index according to a formula; 3, according to a clinical classic TNM staging system, the patients are divided into a TNM staging stage I, a TNM staging stage II, a TNM staging stage III or a TNM staging stage IV; 4, the ALNCR index obtained in the step 2 and the TNM staging result obtained in the step 3 are associated and integrated, and the individualized prognosis score of the ALNCR.TNM composite prognosis model is obtained through calculation. The method is suitable for clinical rapid application; high-risk patients can be accurately distinguished, a quantitative basis is provided for individualized treatment and follow-up visit strategy formulation, and excessive medical treatment or insufficient treatment is reduced.

Provided herein are pharmaceutical compositions and methods for treating COPD or COPD exacerbations in subjects suffering from, for example, moderate COPD, or subjects with decreased eosinophil concentrations, or are suffering from chronic bronchitis. Also provided herein are methods of increasing trough lung function in subjects suffering from moderate COPD. In some aspects, the compound is in an inhalable pharmaceutical composition.

Described herein are methods of managing eosinophilic esophagitis (EoE) in a patient, wherein the patient records the number of episodes of dysphagia on a patient report outcome (PRO) questionnaire prior to and during the course of treatment. While on treatment, the number of episodes of dysphagia are reduced, as reported on the PRO questionnaire. In some embodiments, the esophageal eosinophils are counted before or after treatment, or both. In some embodiments, esophageal eosinophils counts are not correlated with a reduction in the episodes of dysphagia.

Provided herein are methods for reducing the likelihood and / or severity of peripheral neuropathy, anemia, and / or neutropenia in an individual being treated with an antibody-drug conjugate (ADC). Also provided herein are methods for increasing dosing amount and / or frequency of an antibody-drug conjugate (ADC) in an individual. In some embodiments, the methods comprise administering to the individual an effective amount of an ADC that comprises an antibody conjugated to a drug moiety via a linker, wherein the antibody comprises a heavy chain comprising a human Fc region with reduced or eliminated effector function. Compositions, uses, and kits related thereto are also provided.

The invention belongs to the technical field of biological medicine, and relates to application of an OXTR agonist in preparation of a medicine for treating chronic sinusitis (CRS) and respiratory ciliary injury. CRS is treated based on targeted OXTR, and it is found that the OXTR agonist has an excellent treatment effect on promotion of nasal mucosa cilia regeneration and improvement of chronic sinusitis and can promote cilia repair, reduce infiltration of neutrophils and eosinophils and improve the inflammatory environment. In addition, an intranasal treatment dosage form aiming at OXTR is already applied to clinical application of nervous system diseases, the clinical application range of the medicine is expanded, practical feasibility is achieved by improving a better dosage form, and good industrialization prospects are achieved.

The invention discloses application of an SUMO inhibitor 2-D08 in preparation of drugs for treating chronic myelogenous leukemia (CML) and drug resistance of a tyrosine kinase inhibitor (TKI) of the SUMO inhibitor 2-D08. It is revealed for the first time that SUMOylation modification drives disease progression by stabilizing BCR-ABL protein, 2-D08 promotes BCR-ABL protein degradation by inhibiting the modification, and leukemia cell proliferation is remarkably inhibited. In-vitro experiments prove that the compound effectively inhibits the activity of TKI drug-resistant cells, and in-vivo experiments show that 5 mg / kg of the compound can improve liver and spleen infiltration of CML mice. The inhibitor provides a new scheme for overcoming drug resistance, and fills the application blank of SUMOylation modification in CML treatment.

The invention relates to the technical field of small molecule medicines, in particular to a medicine for improving chronic atrophic gastritis and application of the medicine. The invention aims to provide a compound, a pharmaceutical composition containing the compound and application of the compound, the 9, 13-substituted berberine derivative has a good improvement effect on CAG, and further research and observation of the compound on treatment of CAG gastric mucosa gland epithelial cell atrophy, gastric mucosa thinning, gastric mucosa epithelial cell atrophy, gastric mucosa hyperplasia, gastric mucosa epithelial cell atrophy and gastric mucosa hyperplasia. The 9, 13-substituted berberine derivative disclosed by the invention can be used for preventing and / or treating CAG (chorionic gonadotrophin) by virtue of the inhibition effects on infiltration adhesion of a large number of neutrophils and lymphocytes, inflammatory factors and the like.

The invention belongs to the technical field of biological medicines, and particularly discloses a bionic nano-vesicle for regulating and controlling neutrophil phenotype in combination with ultrasound, and a preparation method and application of the bionic nano-vesicle. The bionic nano-vesicle provided by the invention can be broken under the action of high-concentration glutathione existing in a tumor tissue microenvironment to release the sound-sensitive agent and functional siRNA, and under the action of US irradiation, the sound-sensitive agent is activated to generate a large amount of ROS, promote tumor cell DNA breakage, generate a large amount of double-stranded DNA, activate APC and promote IFN-beta release, so that the tumor tissue microenvironment is inhibited. The released functional siRNA can promote the N2-type neutrophile granulocyte to become N1-type neutrophile granulocyte, and the released functional siRNA can prevent the N1-type neutrophile granulocyte from being reversed to the N2-type neutrophile granulocyte again, so that the regulation and control on the phenotype of the neutrophile granulocyte are realized; under catalysis of CAT rich in the thylakoid membrane, H2O2 overexpressed by tumor tissue is decomposed into oxygen, the tumor hypoxia microenvironment can be relieved, and the tumor treatment effect can be improved.

Techniques are disclosed herein that encompass image pre-processing and a semi-supervised clustering for optimization and analysis of immune-enriched single-cell proteomics data generated via multiplexed imaging technologies. This is achieved through an image pre-processing pipeline, which converts image data contained in one type of file (e.g., .mcd) into another type of file (e.g., .tiff) and removes artifact signals from the image data using various algorithms to generate improved image data. Thereafter, a semi-supervised clustering pipeline analyzes the improved image data using various techniques, including implementing a supervised algorithm to identify metaclusters such as general immune phenotypes (e.g., CD4−T-cells, Macrophages, Neutrophils, etc.) as well as non-immune phenotypes while implementing an unsupervised algorithm that enables the identification of specific subclusters and a more in-depth cellular status characterization.

The present invention relates to an anti-neutrophil elastase (NE) antibody or antigen-binding fragment thereof that specifically binds to NE, wherein the anti-NE antibody or antigen-binding fragment thereof comprises: a heavy chain variable region (VH) including a heavy chain CDR1 represented by the amino acid sequence of SEQ ID NO: 1, 7, or 13, a heavy chain CDR2 represented by the amino acid sequence of SEQ ID NO: 2, 8, or 14, and a heavy chain CDR3 represented by the amino acid sequence of SEQ ID NO: 3, 9, or 15; and a light chain variable region (VL) including a light chain CDR1 represented by the amino acid sequence of SEQ ID NO: 4, 10, or 16, a light chain CDR2 represented by the amino acid sequence of SEQ ID NO: 5, 11, or 17, and a light chain CDR3 represented by the amino acid sequence of SEQ ID NO: 6, 12, or 18. The antibody of the present invention exhibits excellent NE neutralizing activity, and thus can be used for preventing or treating NE hyperactivation-related diseases.

A human chronic myeloid leukemia cell line and the use thereof. The human chronic myeloid leukemia cell line is the first cell line internationally established from chronic-phase leukemia cells of chronic myeloid leukemia, and was named human chronic myeloid leukemia cell YYXY-M6, which was deposited at the China Center for Type Culture Collection (Wuhan University, Wuhan, China) on July 24, 2023, under the deposit number of CCTCC NO: C2023219. The leukemia cell line exhibits primitive cell morphology and has three karyotypes, i.e. t(6:11)(q25:q23), del(11)(q23) and normal karyotype (46, XX); is BCR-ABL gene-negative; has good in-vitro proliferation ability; can be used as cellular material for the study of the mechanism of occurrence and development of the chronic phase of chronic myeloid leukemia, from the chronic phase thereof to the blastic phase thereof, and of BCR-ABL gene-negative chronic myeloid leukemia, and for the in-vitro study of individualized treatment; and can also be used for both in-vitro and in-vivo studies of drug screening and evaluation for the chronic phase of chronic myeloid leukemia, from the chronic phase thereof to the blastic phase thereof, and BCR-ABL gene-negative chronic myeloid leukemia, providing guidance for clinical medication.

This disclosure describes methods of and systems for screening for sepsis or septic shock in a patient and methods of ruling out sepsis or septic shock in a patient using white blood cell count (WBC), a monocyte cell population parameter, or neutrophil-to-lymphocyte ratio (NLR), or a combination thereof, in the blood sample from the patient.

The present invention provides methods of producing in vitro derived neutrophils or macrophages in xenogen- and serum-free conditions from pluripotent stem cells and in vitro derived populations of neutrophils and macrophages. Methods of treatment using in vitro derived neutrophils or macrophages are also contemplated.

The invention provides an antibiotic-free host-plasmid TA maintenance system and application thereof, and relates to the technical field of gene engineering. According to the invention, a toxin gene CcdB is accurately integrated to a host escherichia coli chromosome fhuA site through a gene editing technology, and accurate control of toxin expression is realized by adopting an inducible promoter. The antitoxin gene is simplified to a plasmid skeleton, and the toxin inhibition function is maintained through constitutive expression. According to the method, plasmid-free cells are eliminated through arabinose-induced toxin expression, so that stable maintenance of plasmids is realized (the loss rate is lt; and the method completely avoids the use of antibiotics, meets the biological safety requirements, is suitable for large-scale production of vaccines, recombinant proteins and other biological products, and has the advantages of high plasmid yield, low environmental leakage risk, process compatibility and the like.